ADCTADC Therapeutics SA
- PR Newswire
ADC Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure Improvements
$86.6 Million Private Placement announced, with participation from new and existing investors, extending expected cash runway into 2029 HealthCare Royalty financing agreement amended, removing change-of-control ...
- Earnings Call Transcripts
Genmab Morgan Stanley 24th Annual Global Healthcare Conference - ADC THERAPEUTICS SA
This session at the Morgan Stanley Global Healthcare Conference, we're very excited to have the team from GENMAB, Jan and Tayi, with us. Let me just get through a quick disclosure. For important disclosures, please see t ...
- Earnings Call Transcripts
Genmab Morgan Stanley 24th Annual Global Healthcare Conference - ADC THERAPEUTICS SA
This session at the Morgan Stanley Global Healthcare Conference, we're very excited to have the team from GENMAB, Jan and Tayi, with us. Let me just get through a quick disclosure. For important disclosures, please see t ...
- Earnings Call Transcripts
WELLS FARGO 21ST ANNUAL HEALTHCARE CONFERENCE - ADC THERAPEUTICS SA
Okay, so we're ready for our next panel. I have here with me today Judith, CBO of GenMap. Thanks so much for joining us. Thank you for having me. Perfect. So maybe we can start with, you know, kind of introductory questi ...
- PR Newswire
ADC Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the 2026 Cantor... ...
- Analyst Upgrades
Guggenheim Maintains Buy on ADC Therapeutics, Lowers Price Target to $5
Guggenheim analyst Michael Schmidt maintains ADC Therapeutics with a Buy and lowers the price target from $10 to $5. ...
- Earnings Call Transcripts
ADC Therapeutics Q2 2026 Earnings - ADC THERAPEUTICS SA
Good morning, ladies and gentlemen, and welcome to the ADC Therapeutics Q2 2026 Earnings Conference Call. At this time, all lines are in listen-only mode. Following the presentation, we will conduct a question-and-answer ...
- PR Newswire
ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates
Second quarter 2026 net product revenue of $18.6 million; cash and cash equivalents of $219.1 million as of June 30, 2026LOTIS-7, LOTIS-5 and MZL IIT data submitted for presentation at ASHCompany evaluating regulatory ...
- PR Newswire
ADC Therapeutics to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that... ...
- PR Newswire
ADC Therapeutics Announces New Employee Inducement Grant
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that... ...
- PR Newswire
ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination Trial
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced the... ...
- PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC" or the "Company") (NYSE: ADCT). Such investors are advised ... ...
- PR Newswire
ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA® Growth Opportunities and Regulatory Priorities
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced a... ...
- PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC" or the "Company") (NYSE: ADCT). Such investors are advised ... ...
- PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC" or the "Company") (NYSE: ADCT). Such investors are advised ... ...
- Analyst Upgrades
This ADC Therapeutics Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Monday
Top Wall Street analysts changed outlook on top names. ADCT downgraded See analysts' views. ...
- Analyst Upgrades
HC Wainwright & Co. Downgrades ADC Therapeutics to Neutral
HC Wainwright & Co. analyst Robert Burns downgrades ADC Therapeutics from Buy to Neutral. ...
- Analyst Upgrades
RBC Capital Downgrades ADC Therapeutics to Sector Perform, Lowers Price Target to $2
RBC Capital analyst Leonid Timashev downgrades ADC Therapeutics from Outperform to Sector Perform and lowers the price target from $6 to $2. ...
- PR Newswire
ADC Therapeutics Announces Results From LOTIS-5 Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
ADC Therapeutics SA (NYSE: ADCT) today announced topline data from its Phase 3 LOTIS-5 confirmatory trial evaluating ZYNLONTA® (loncastuximab... ...
- Analyst Upgrades
RBC Capital Reiterates Outperform on ADC Therapeutics, Maintains $6 Price Target
RBC Capital analyst Leonid Timashev reiterates ADC Therapeutics with a Outperform and maintains $6 price target. ...
- Analyst Upgrades
HC Wainwright & Co. Reiterates Buy on ADC Therapeutics, Maintains $8 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates ADC Therapeutics with a Buy and maintains $8 price target. ...
- PR Newswire
ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported... ...
- PR Newswire
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that... ...
- PR Newswire
ADC Therapeutics to Host First Quarter 2026 Financial Results Conference Call on May 4, 2026
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that... ...
- PR Newswire
ADC Therapeutics Announces New Employee Inducement Grant
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that... ...